Evidence map›Paper›PMID 22848572›Full record

ArticlePloS one2012

Development of a novel in silico docking simulation model for the fine HIV-1 cytotoxic T lymphocyte epitope mapping.

Masahiko Mori, Kei Matsuki, Tomoyuki Maekawa, Mari Tanaka, Busarawan Sriwanthana, Masaru Yokoyama, Koya Ariyoshi

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Masahiko MoriInstitute of Tropical Medicine, Nagasaki University, Nagasaki City, Nagasaki, Japan.
Kei Matsuki
Tomoyuki Maekawa
Mari Tanaka
Busarawan Sriwanthana
Masaru Yokoyama
Koya Ariyoshi
Nagasaki University · JPMinistry of Public Health · THNational Institute of Infectious Diseases · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionClass I HLA's polymorphism has hampered CTL epitope mapping with laborious experiments. Objectives are 1) to evaluate the novel in silico model in predicting previously reported epitopes in comparison with existing program, and 2) to apply the model to predict optimal epitopes with HLA using experimental results. MATERIALS AND

methodsWe have developed a novel in silico epitope prediction method, based on HLA crystal structure and a peptide docking simulation model, calculating the peptide-HLA binding affinity at four amino acid residues in each terminal. It was applied to predict 52 HIV best-defined CTL epitopes from 15-mer overlapping peptides, and its predictive ability was compared with the HLA binding motif-based program of HLArestrictor. It was then used to predict HIV-1 Gag optimal epitopes from previous ELISpot results.

results43/52 (82.7%) epitopes were detected by the novel model, whereas 37 (71.2%) by HLArestrictor. We also found a significant reduction in epitope detection rates for longer epitopes in HLArestrictor (p = 0.027), but not in the novel model. Improved epitope prediction was also found by introducing both models, especially in specificity (p<0.001). Eight peptides were predicted as novel, immunodominant epitopes in both models. DISCUSSION: This novel model can predict optimal CTL epitopes, which were not detected by an existing program. This model is potentially useful not only for narrowing down optimal epitopes, but predicting rare HLA alleles with less information. By introducing different principal models, epitope prediction will be more precise.

Indexed as

Computational BiologyMolecular Docking SimulationAmino Acid MotifsAmino Acid SequenceCohort StudiesEpitope MappingEpitopes, T-LymphocyteFemalegag Gene Products, Human Immunodeficiency VirusHIV-1HIV AntigensHLA AntigensHumansMaleT-Lymphocytes, CytotoxicEpitopes, T-Lymphocytegag Gene Products, Human Immunodeficiency VirusHIV AntigensHLA Antigens

Identifiers

PMID22848572
PMCPMC3407191
OpenAlexW2097656644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.